Emerging growth companies continue to focus on commercialization, manufacturing readiness, artificial intelligence ...

The company has now raised more than $350 million since 2018. The new funding will support a global trial of its experimental ...

It's been a volatile year for the company, but don't let that scare you away.

Biotech is the story at midday Friday, and it’s not a pretty one for shareholders who chased the sector’s monster 2026 run.

The “sell AI” trade that started in early summer has quietly grown a positive side, and that side is healthcare.

Abbott and Danaher both reported Q1 2026 results, but the businesses underneath those numbers point in opposite directions, ...

The company outlined a new business strategy combining peptide research, AI-enabled discovery, and a planned U. S.

Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals, has executed a Business Transfer Agreement for transfer of its mRNA business as a going concern on a slump sale basis for a cash ...

Why does getting family health insurance through a job cost as much as buying a new car? And who might be the new FDA ...

June 2026 saw drug development in oncology and neurology continue and biotech deals over small molecules and RNA therapies ...

A smart beta exchange traded fund, the First Trust NYSE Arca Biotechnology ETF (FBT) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market. What Are Smart ...

Greenland Mines Ltd (Nasdaq: GRML) ("Greenland Mines" or the "Company") today announced that IP Australia has granted Australian Patent No. 2023252508, entitled "Treatment of Neuromuscular Diseases ...